JAMA Network
About The Study: In this cohort study, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with reduced risk of developing nonexudative age-related macular degeneration (AMD) but was not associated with progression to exudative AMD among individuals with nonexudative AMD. These findings may inform future randomized trials evaluating the ocular effects of GLP-1RAs in nondiabetic populations.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
